Low-Dose Metronomic Topotecan and Pazopanib (TOPAZ) in Children with Relapsed or Refractory Solid Tumors: A C17 Canadian Phase I Clinical Trial

Low-Dose Metronomic Topotecan and Pazopanib (TOPAZ) in Children with Relapsed or Refractory Solid Tumors: A C17 Canadian Phase I Clinical Trial

Oral metronomic topotecan represents a novel approach to chemotherapy delivery which, in preclinical models, may work synergistically with pazopanib in targeting angiogenesis. A phase I and pharmacokinetic (PK) study of this combination was performed in children with relapsed/refractory solid tumors...

Full description

Bibliographic Details
Main Authors: Arif Manji, Yvan Samson, Rebecca J. Deyell, Donna L. Johnston, Victor A. Lewis, Alexandra P. Zorzi, Jason N. Berman, Kathy Brodeur-Robb, Ellen Morrison, Lynn Kee, Sushil Kumar, Sylvain Baruchel, James A. Whitlock, Daniel A. Morgenstern
Format: Article
Language:English
Published: MDPI AG 2022-06-01
Series:Cancers
Subjects:
phase I trial
pediatric
children
pazopanib
topotecan
metronomic
Online Access:https://www.mdpi.com/2072-6694/14/12/2985

Internet

https://www.mdpi.com/2072-6694/14/12/2985

Similar Items